Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 4/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12350647 | 0.83 | PRMT5 (0.41) | HIF1AAAK1USP30PRMT5WDR77 | |
| SCHEMBL4442924 | 0.82 | ALOX5AP (0.41) | ALOX5APPPARDPPARG | |
| SCHEMBL8194015 | 0.78 | USP30 (0.41) | HIF1AAAK1USP30PRMT5WDR77 | |
| SCHEMBL1678552 | 0.71 | NR1H2 (0.62) | HIF1AAAK1 | |
| SCHEMBL14191741 | 0.71 | RAB9A (0.41) | HIF1ANPC1 | |
| SCHEMBL481893 | 0.71 | USP30 (0.43) | HIF1AAAK1USP30PRMT5WDR77 | |
| SCHEMBL27110645 | 0.71 | USP30 (0.41) | HIF1AAAK1USP30PRMT5WDR77 | |
| SCHEMBL150595 | 0.70 | USP30 (0.41) | HIF1AAAK1USP30PRMT5WDR77 | |
| SCHEMBL22724916 | 0.69 | USP30 (0.40) | HIF1AAAK1USP30PRMT5WDR77 | |
| SCHEMBL12172282 | 0.69 | PRMT5 (0.43) | HIF1AAAK1USP30PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2124563-B1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-29 | — | — | EP | disclosed |
| EP-2124563-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-12-02 | — | — | EP | disclosed |
| US-7612211-B2 | Benzimidazole TRPV1 inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-03 | — | — | US | disclosed |
| US-7612211-B2 | Benzimidazole TRPV1 inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-03 | — | — | US | disclosed |
| US-7612211-B2 | Benzimidazole TRPV1 inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-03 | — | — | US | disclosed |
| WO-2008076752-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-19 | — | — | US | disclosed |
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | TRPV1, TRPV2, TRPA1 | HIF1A 1292/4885AAK1 2021/4885ALOX5AP 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.